 The primary objective of the study is to improve pathological complete response rates with the addition of dual EGFR blockade. Neoadjuvant chemotherapy which achieves pathologic complete responses pCR has been shown to predict improved long-term survival and serves as a surrogate for clinical outcome. By using this primary endpoint we can obtain statistical data with smaller patient numbers and at a lower overall cost. Additionally, we hope to correlate clinical and radiologic outcomes with gene expression data. 